DFD-29 from Journey Medical may best out Oracea

Written by on July 5, 2023 in Minocycline, New Rosacea Treatments with 1 Comment

Journey Medical Corporation are readying to release their Phase 3 clinical trial data for DFD-29, their delayed release 40mg minocycline treatment for rosacea. Targeted as a competitor to Galderma’s successful doxycycline based Oracea, the yet to be named DFD-29 is expected to release clinical data that will demonstrate superior treatment results.

According to Journey Medical’s Q1 2023 Investor Presentation, DFD-29 has the potential to be superior to Oracea in both inflammatory lesion count and overall treatment success. The reported side effects of DFD-29 are similar to Oracea.

Keep an eye out for the official announcement of the Phase 3 data in the coming weeks.

When will DFD-29 be released?

According to Journey Medical FDA Approval could occur as soon as the second half of 2024.

Journey Medical is the owner of the topical 1.5% minocycline foam ZILXI.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. Jane says:

    Thanks for continuing to keep us all up to date regarding new treatments and management of rosacea. Great information for a difficult condition.

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.